<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531687</url>
  </required_header>
  <id_info>
    <org_study_id>Relapse testis cancer 2007</org_study_id>
    <nct_id>NCT00531687</nct_id>
  </id_info>
  <brief_title>Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer</brief_title>
  <official_title>Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives:

      Primary objective

        -  The primary objective of this study is to investigate the combination of
           cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with
           germ cell tumours previously treated with BEP.

      Secondary Objectives

        -  Overall survival

        -  Progression free survival

        -  Response rates (RECIST)

        -  Duration of response

        -  To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients
           previously treated with BEP
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      not relevant
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP. · ·</measure>
    <time_frame>December 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives · Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives · Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives · Response rates (RECIST)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives · Duration of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives · To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Testicular Cancer</condition>
  <arm_group>
    <arm_group_label>GCT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cisplatin Paclitaxel gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m2 day 1 (3 hour infusion)
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.</description>
    <arm_group_label>GCT</arm_group_label>
    <other_name>taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin 50 mg/m2 day 1 and 2
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.</description>
    <arm_group_label>GCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered</description>
    <arm_group_label>GCT</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed germ cell tumor (seminoma or non-seminoma) with measurable
             metastatic disease either by radiography (at a site which has previously not been
             irradiated) or elevation of alpha fetoprotein (AFP) and/or elevation of beta-human
             chorionic gonadotropin (beta-HCG);

          -  Patient previously treated with standard BEP (3 or 4 cycles) with relapse 1 months or
             more after favorable response on previous chemotherapy (CR or PR)

          -  Male

          -  Age greater than or equal to 18 years;

          -  Performance status 0,1,2 or 3

          -  WBC &gt; 3000 mill/l, ANC &gt; 1500 mill/l, platelet count &gt; 100.000 mill/l; serum bilirubin
             &lt; 1.5 x the upper limit of normal;

          -  Adequate renal function (Glomerular Filtration Rate (GFR) &gt;60 ml/min). GFR will be
             assessed by direct measurement (EDTA clearance or creatinine clearance)

          -  signed informed consent;

        Exclusion Criteria:

          -  Uncontrolled active severe clinical infection (CTC grade 3 or 4).

          -  Serious concomitant systemic disorders incompatible with the study (at the discretion
             of the investigator), including expected difficulty of follow-up related to mental
             disorders.

          -  Grade 2 or greater peripheral neuropathy according to the CTC, version 3.0.

          -  Second malignancy other than basal or squamous cell skin cancer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gedske Daugaard, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology 5073, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Gedske Daugaard</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

